Clinical Research Directory

Inclusion Criteria: * Participants aged ≥40 years at the time of signing the ICF. * Diagnosis of IPF within 7 years prior to the screening visit, confirmed by centrally reviewed high-resolution computed tomography (HRCT) of the chest (performed during screening period). * Confirmed pulmonary function criteria at screening, as follows: 1. FVC ≥45% predicted of normal, as determined by spirometry, 2. FEV1/FVC \>0.7 or LLN, as determined by spirometry, 3. Diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin ≥25% predicted of normal * On standard of care for the treatment of IPF at a stable dose for at least 8 weeks before the screening visit, and during the screening period; or not on antifibrotic treatment and stable for at least 4 weeks before the screening visit (naïve or intolerant). * Women of non childbearing potential (WONCBP) or male participants willing to comply with this protocol's requirements regarding contraception. Exclusion Criteria: * Diagnosis of fibrosing interstitial lung disease other than IPF. * Acute IPF exacerbation within 6 months prior to screening and/or during the screening period. * Lower respiratory tract infection requiring treatment within 4 weeks prior to screening and/or during the screening period. * History of lung volume reduction surgery or lung transplant or major surgery performed within 3 months prior to baseline or planned during the trial (being on a transplant list is allowed). * Systemic or opportunistic infections including: 1. Active infection with human immunodeficiency virus. 2. Known current tuberculosis infection. 3. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). 4. Chronic HCV (positive hepatitis C virus antibody \[HCVAb\] and hepatitis C virus \[HCV\] RNA). * Concurrent or previous participation in another clinical trial and received investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to screening.